MX9305855A - Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad. - Google Patents

Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.

Info

Publication number
MX9305855A
MX9305855A MX9305855A MX9305855A MX9305855A MX 9305855 A MX9305855 A MX 9305855A MX 9305855 A MX9305855 A MX 9305855A MX 9305855 A MX9305855 A MX 9305855A MX 9305855 A MX9305855 A MX 9305855A
Authority
MX
Mexico
Prior art keywords
tumorigenic
cell
propensity
become
latumorigenicity
Prior art date
Application number
MX9305855A
Other languages
English (en)
Inventor
Tadatsugu Taniguchi
Cheryl L Willman
Maria G Pallavicini
Hisashi Harada
Noboyuki Tanaka
Original Assignee
Tadatsugu Taniguchi
Willman C
Pallavicini M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tadatsugu Taniguchi, Willman C, Pallavicini M filed Critical Tadatsugu Taniguchi
Publication of MX9305855A publication Critical patent/MX9305855A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere, en general, a un método paradiagnosticar células tumorígenas de mamífero o la propensión de una célulade mamífero para llegar a ser tumorígena. Adicionalmente, la presenteinvención se refiere a un CDNA o DNA genómico clonado para reducir lapropensión de una célula para llegar a ser tumorígena o suprimir elfenotipo tumorígeno de una célula; un método para reducir la propensión deuna célula para llegar a ser tumorígena o suprimir el fenotipo tumorígenode una célula; un método de tratamiento de un paciente que padece o estápredispuesto a desarrollar subsiguientemente cáncer; y un método paradiagnosticar tejido tumorígeno de un ser humano o tejido predispuesto parallegar a ser tumorígeno.
MX9305855A 1992-09-24 1993-09-23 Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad. MX9305855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95057492A 1992-09-24 1992-09-24
US99559492A 1992-12-22 1992-12-22

Publications (1)

Publication Number Publication Date
MX9305855A true MX9305855A (es) 1995-01-31

Family

ID=27130304

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305855A MX9305855A (es) 1992-09-24 1993-09-23 Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.

Country Status (10)

Country Link
US (2) US5652095A (es)
EP (1) EP0662976A4 (es)
JP (1) JPH08501691A (es)
CN (1) CN1051110C (es)
AU (1) AU682321B2 (es)
CA (1) CA2145412A1 (es)
HU (1) HU217688B (es)
MX (1) MX9305855A (es)
NZ (1) NZ256623A (es)
WO (1) WO1994006818A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
EP0648493A1 (en) * 1993-10-19 1995-04-19 Tadatsugu Prof. Dr. Taniguchi A method to reverse the phenotype of transformed cells by the transcription factor IRF-1
PH31414A (en) * 1994-02-24 1998-10-29 Boehringer Ingelheim Int Method of diagnosing cancer precancerous state, orsusceptibility to other forms of diseases by anal ysis of irf-1 specific rna in biopsy samples.
US6638502B1 (en) * 1997-04-28 2003-10-28 Gencell Sas Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
ES2307526T3 (es) 1999-08-23 2008-12-01 Chugai Seiyaku Kabushiki Kaisha Potenciadores de la expresion del antigeno hm1.24.
JP4522431B2 (ja) * 2001-02-07 2010-08-11 中外製薬株式会社 造血器腫瘍の治療剤
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
WO2002068614A2 (en) * 2001-02-26 2002-09-06 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
JP2004532213A (ja) * 2001-04-06 2004-10-21 ザ ユニヴァーシティ オヴ シカゴ Ｅｇｒ−１プロモーター活性の化学療法誘導
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
CN108221058A (zh) * 2017-12-29 2018-06-29 苏州金唯智生物科技有限公司 一种猪全基因组sgRNA文库及其构建方法和应用
CN108205614A (zh) * 2017-12-29 2018-06-26 苏州金唯智生物科技有限公司 一种全基因组sgRNA文库的构建系统及其应用
EP4114448A4 (en) * 2020-03-06 2024-04-03 University of Pittsburgh - Of the Commonwealth System of Higher Education ONCOLYTIC VIRUSES EXPRESSING AN IRF MODULATOR FOR THE TREATMENT OF CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE208817T1 (de) * 1988-08-24 2001-11-15 Tadatsugu Taniguchi Gen-expression regulierender faktor
CA2104964A1 (en) * 1991-02-28 1992-08-29 Ruth Sager Cancer diagnosis and therapy with tumor suppressor genes

Also Published As

Publication number Publication date
WO1994006818A1 (en) 1994-03-31
HUT71768A (en) 1996-01-29
US5652095A (en) 1997-07-29
AU682321B2 (en) 1997-10-02
JPH08501691A (ja) 1996-02-27
AU5141793A (en) 1994-04-12
CA2145412A1 (en) 1994-03-31
CN1098140A (zh) 1995-02-01
EP0662976A4 (en) 1997-04-23
CN1051110C (zh) 2000-04-05
HU9500841D0 (en) 1995-05-29
US5807836A (en) 1998-09-15
HU217688B (hu) 2000-03-28
EP0662976A1 (en) 1995-07-19
NZ256623A (en) 1997-04-24

Similar Documents

Publication Publication Date Title
MX9305855A (es) Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
Kim et al. The radiosensitization of hypoxic tumor cells by hyperthermia
Blum The physiological effects of sunlight on man
US5814078A (en) Method and apparatus for regulating and improving the status of development and survival of living organisms
RO93650B (ro) Procedeu pentru obtinerea unei polipeptide umane fiziologic activa
PT651636E (pt) Quimioterapia contra o cancro
Finkelstein et al. Large group awareness training.
Cohrs et al. Effect of vitamin E succinate and a cAMP-Stimulating agent on the expression of c-myc, N-myc and H-ras in murine neuroblastoma cells
Schafer Narratives of the self.
van den Aardweg et al. Dose fractionation effects in primary and metastatic human uveal melanoma cell lines
Golan et al. Increased photosensitivity to near-ultraviolet light in murine SLE.
DE3585061D1 (de) Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnose- oder therapieverfahren bezueglich krebskrankheiten.
Blitzer et al. Blood pressure and hemoglobin concentration: multivariate analysis of local control after irradiation for head and neck cancer
Mivechi et al. Lack of development of thermotolerance in early progenitors of murine bone marrow cells
Jakobsson et al. Fractionation scheme with low individual tumour dose and high total dose
Rolfs et al. Guiding the unconscious: The process of poem selection for poetry therapy groups.
Bodansky Mechanism of action of methylene blue in treatment of methemoglobinemia
Reyes et al. Trisomy 8 mosaicism syndrome. Report of monozygotic twins
Giannelli et al. Xeroderma pigmentosum and medulloblastoma: chromosomal damage to lymphocytes during radiotherapy
Kakar et al. Solitary plasmacytoma larynx
Christensen et al. Unwanted side effects and optimization of phototherapy
AU3681695A (en) Cell growth regulator
Walker et al. Nasolabial flap reconstruction for carcinoma of the lower lip: An eleven year follow-up study
TAKATSUKA et al. SURGICAL TREATMENT OF EARLY BREAST CANCER
Binkley FIVE YEAR CURE OR CONTROLLED FIVE YEARS?

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees